Analytical Data
-
Gene name
CDK2-CCNO
- Application
-
Alternative Names
CDKN2; p33(CDK2); Cell division protein kinase 2; p33 protein kinase
-
Species
Rat
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q63699
-
Expression Region
Ser94~Leu212
-
Molecular Weight
41kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK2 (Cyclin-Dependent Kinase 2) is a crucial enzyme that plays a significant role in cell cycle regulation, particularly during the transition from the G1 phase to the S phase. It is activated by binding to specific cyclins, with cyclin E and cyclin A being the most notable partners. CCNO (Cyclin O) is an atypical cyclin that has been implicated in various cellular processes, including cell proliferation and response to DNA damage. Recent studies suggest that the CDK2-CCNO complex may have distinct functions compared to other CDK-cyclin complexes, particularly in the regulation of the cell cycle and potential involvement in oncogenic pathways. The reconstitution and functional characterization of the CDK2-CCNO fusion protein provide insights into the unique biochemical properties and cellular roles of this complex. Understanding the mechanisms by which CDK2-CCNO modulates cell cycle progression could unveil new therapeutic targets for cancer treatment, especially in tumors exhibiting dysregulation of cell cycle machinery. The ongoing research aims to elucidate the structural dynamics, regulatory mechanisms, and functional implications of the CDK2-CCNO interaction, highlighting its importance in maintaining cellular homeostasis and its potential role in cancer biology.
